Tango Therapeutics, Inc.

About Tango Therapeutics, Inc.

Tango Therapeutics is a biotechnology company focused on leveraging the principle of synthetic lethality to develop medicines that target specific tumors, aiming to expand the reach of genetically targeted therapies with a patient-centric approach.

Products & Services

Pipeline:A robust pipeline of therapeutic programs targeting specific tumors.

PRMT5 Program:A specific program focused on PRMT5 as a therapeutic target.

CoREST Program:A program targeting CoREST for therapeutic development.

Specialties

Synthetic Lethality Genetically Targeted Therapies Tumor-Specific Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Offering and PIPE T: - FT: Underwritten Offering and PIPE	A: 225000000 MR: - FA: $225 million FAN: 225000000	D: 2025-10-23 FD: 2025-10-23	12 investors
2	RT: PIPE T: - FT: PIPE	A: 80000000 MR: - FA: $80 million FAN: 80000000	D: 2023-08-10 FD: 2023-08-10	8 investors

Underwritten Offering and PIPE Latest

2025-10-23

$225.0M

12 investors (Pro only)

PIPE 2023-08-10

$80.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Barbara Weber

President and CEO

A

Adam Crystal

President, Research & Development

D

Daniella Beckman

Chief Financial Officer

J

Jannik N. Andersen

Chief Scientific Officer

D

Doug Barry

Chief Legal Officer

J

Julie Carretero

Chief Human Resources Officer

View 25 more team members with Pro

Unlock Full Team Directory

Recent News